Myeloid malignancies with acquired trisomy 21 as the sole cytogenetic change are clinically highly variable and display a heterogeneous pattern of copy number alterations and mutations

European Journal of Haematology

Volumn 88, Issue 2, 2012, Pages 136-143

  Larsson, Nina ^a   Lilljebjörn, Henrik ^a   Lassen, Carin ^a   Johansson, Bertil ^a   Fioretos, Thoas ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Age; Gene mutations; Genomic imbalances; Myeloid malignancies; Trisomy 21

Indexed keywords

CD135 ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; JANUS KINASE 2; NUCLEOPHOSMIN; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; CYTOGENETICS; DISEASE ASSOCIATION; FEMALE; GENE DELETION; GENE DOSAGE; GENE DUPLICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; MALE; MORPHOLOGY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; ONCOGENE N RAS; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRISOMY 21; UNIPARENTAL DISOMY;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 21; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS; KARYOTYPE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; POLYMORPHISM, SINGLE NUCLEOTIDE; TRISOMY; YOUNG ADULT;

EID: 84855830306     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01710.x     Document Type: Article

References (54)

1. Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations and gene fusions in cancer. 2011.
2. Mitelman F, Nilsson PG, Brandt L, Alimena G, Gastaldi R, Dallapiccola B. Chromosome pattern, occupation, and clinical features in patients with acute non-lymphocytic leukemia. Cancer Genet Cytogenet 1981;4:197-214.
3. Billström R, Nilsson P-G, Mitelman F. Characteristic patterns of chromosome abnormalities in acute myeloid leukemia with Auer rods. Cancer Genet Cytogenet 1987;28:191-9.
4. Schaich M, Harbich-Brutscher E, Pascheberg U, Mohr B, Soucek S, Ehninger G, Illmer T. Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome. Haematologica 2002;87:455-64.
5. Cortes JE, Kantarjian H, O'Brien S, Keating M, Pierce S, Freireich EJ, Estay E. Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. Leukemia 1995;9:115-7.
6. Gale RP, Horowitz MM, Weiner RS, et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 1995;16:203-8.
7. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. Blood 1998;92:2322-33.
8. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-20.
9. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36.
10. Chalandon Y, Barnett MJ, Horsman DE, et al. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant 2002;8:435-43.
11. Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002;100:2717-23.
12. Tavernier E, Le Q-H, Elhamri M, Thomas X. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors. Leuk Res 2003;27:205-14.
13. Stark B, Jeison M, Gabay LG, et al. Classical and molecular cytogenetic abnormalities and outcome of childhood acute myeloid leukaemia: report from a referral centre in Israel. Br J Haematol 2004;126:320-37.
14. Baz R, Rodriguez C, Fu AZ, Jawde RA, Kalaycio M, Advani A, Sobecks R, Sekeres MA. Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia. Cancer 2007;110:1752-9.
15. Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol 2010;28:2674-81.
16. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354-65.
17. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-35.
18. Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60years of age: Cancer and Leukemia Group B study 9222. Blood 2005;105:3420-7.
19. Bacher U, Kern W, Schnittger S, Hiddemann W, Schoch C, Haferlach T. Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2, 235 patients. Ann Hematol 2005;84:785-91.
20. Barbaric D, Alonzo TA, Gerbing RB, Meshinchi S, Heerema NA, Barnard DR, Lange BJ, Woods WG, Arceci RJ, Smith FO. Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961. Blood 2007;109:2314-21.
21. De Vita S, Canzonetta C, Mulligan C, et al. Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome. Oncogene 2010;29:6102-14.
22. Ng AP, Hyland CD, Metcalf D, Carmichael CL, Loughran SJ, Di Rago L, Kile BT, Alexander WS. Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome. Blood 2010;115:3966-9.
23. Preudhomme C, Warot-Loze D, Roumier C, et al. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2αB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood 2000;96:2862-9.
24. Taketani T, Taki T, Takita J, Tsuchida M, Hanada R, Hongo T, Kaneko T, Manabe A, Ida K, Hayashi Y. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies. Genes Chromosom Cancer 2003;38:1-7.
25. Roche-Lestienne C, Deluche L, Corm S, Tigaud I, Joha S, Philippe N, Geffroy S, Laï JL, Nicolini FE, Preudhomme C. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood 2008;111:3735-41.
26. Gondek LP, Dunbar AJ, Szpurka H, McDevitt MA, Maciejewski JP. SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. PLoS ONE 2007;2:e1225.
27. Nowak D, Nolte F, Mossner M, Nowak V, Baldus CD, Hopfer O, Noll S, Thiel E, Wagner F, Hofmann WK. Genome-wide DNA-mapping of CD34+ cells from patients with myelodysplastic syndrome using 500K SNP arrays identifies significant regions of deletion and uniparental disomy. Exp Hematol 2009;37:215-24.
28. Parkin B, Erba H, Ouillette P, et al. Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. Blood 2010;116:4958-67.
29. Flach J, Dicker F, Schnittger S, Schindela S, Kohlmann A, Haferlach T, Kern W, Haferlach C. An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling. Leukemia 2011;25:713-8.
30. Heim S, Békassy AN, Garwicz S, Heldrup J, Kristoffersson U, Mandahl N, Wiebe T, Mitelman F. Bone marrow karyotypes in 94 children with acute leukemia. Eur J Haematol 1990;44:227-33.
31. Johansson B, Billström R, Broberg K, Fioretos T, Nilsson P-G, Ahlgren T, Malm C, Samuelsson BO, Mitelman F. Cytogenetic polyclonality in hematologic malignancies. Genes Chromosom Cancer 1999;24:222-9.
32. Lin M, Wei L-J, Sellers WR, Lieberfarb M, Wong WH, Li C. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 2004;20:1233-40.
33. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007;23:657-63.
34. Beroukhim R, Lin M, Park Y, et al. Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol 2006;2:326-32.
35. The International HapMap Consortium. A haplotype map of the human genome. Nature 2005;437:1299-320.
36. Larsson N, Billström R, Lilljebjörn H, Lassen C, Richter J, Ekblom M, Fioretos T. Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells. Cancer Genet Cytogenet 2010;199:89-95.
37. Paulsson K, Haferlach C, Fonatsch C, Hagemeijer A, Andersen MK, Slovak ML, Johansson B. The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations. Hum Mol Genet 2010;19:1507-14.
38. Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalova K, Stark B, Harrison CJ, Teigler-Schlegel A, Johansson B. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood 2008;111:1575-83.
39. Cheng Y, Wang H, Wang H, Chen Z, Jin J. Trisomy 21 in patients with acute leukemia. Am J Hematol 2009;84:193-4.
40. Johansson B, Mertens F, Mitelman F. Cytogenetic deletion maps of hematologic neoplasms: circumstantial evidence for tumor suppressor loci. Genes Chromosom Cancer 1993;8:205-18.
41. Le Beau MM, Espinosa R III, Davis EM, Eisenbart JD, Larson RA, Green ED. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996;88:1930-5.
42. Rücker FG, Bullinger L, Schwaenen C, et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 2006;24:3887-94.
43. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008;111:1534-42.
44. Nikoloski G, Langemeijer SMC, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010;42:665-7.
45. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010;42:722-6.
46. Klampfl T, Harutyunyan A, Berg T, et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 2011;118:167-76.
47. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-301.
48. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, O'Keefe CL, Ganetzky R, McDevitt MA, Maciejewski JP. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009;113:6403-10.
49. Langemeijer SMC, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009;41:838-42.
50. Mohamedali AM, Smith AE, Gaken J, Lea NC, Mian SA, Westwood NB, Strupp C, Gattermann N, Germing U, Mufti GJ. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 2009;27:4002-6.
51. Osato M, Asou N, Abdalla E, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2αβ gene associated with myeloblastic leukemias. Blood 1999;93:1817-24.
52. Tahirov TH, Inoue-Bungo T, Morii H, et al. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFβ. Cell 2001;104:755-67.
53. Watanabe-Okochi N, Kitaura J, Ono R, Harada H, Harada Y, Komeno Y, Nakajima H, Nosaka T, Inaba T, Kitamura T. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 2008;111:4297-308.
54. Ding Y, Harada Y, Imagawa J, Kimura A, Harada H. AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood 2009;114:5201-5.